DiaMedica Therapeutics (DMAC) stock, explained like you're 5

Is DiaMedica Therapeutics a small, medium or large cap company?

No. DiaMedica Therapeutics is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 449 million dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How DiaMedica Therapeutics makes money

• Selling medicines, medical devices or healthcare services.
• Insurance premiums or hospital and clinic fees.
• Research and licensing deals.

What moves DMAC stock

• Results from clinical trials and approvals from regulators.
• Drug prices, insurance rules and government policy.
• Patents running out and new competing treatments.

In the news lately

• DMAC Oct 2026 2.500 call (DMAC261016C00002500) stock price, news, quote and history (Yahoo Finance UK)
• DMAC Forecast Price Target Prediction for 2027 (TradingView)
• A drug candidate was used for the first time in a trial for babies growing too slowly. Findings are set for Oct. 23. (Stock Titan)
• Should I buy DiaMedica Therapeutics (DMAC) (Zacks Investment Research)
• DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026 (Business Wire)

Key terms to know before you follow DMAC

• Market cap
• P/E ratio
• EPS (earnings per share)
• Earnings report
• Volatility